World Re-knowned Team with a proven Track Record

Tania holds a Ph.D. in Molecular Biology from UNL (Lisbon, Portugal) in collaboration with Harvard Medical School and Caen University (France). Her academic journey also includes a MSc in Clinical Microbiology in collaboration with Lausanne University (Switzerland) and a BSc in Biochemistry. Additionally, Tania has acquired professional certifications in Project Management and Clinical Trials Monitoring.

Adrian Bot, M.D., Ph.D. is a biopharma executive with three decades of experience in research and development with a focus on immune, cell, gene therapy and nanomedicines. Most recently, he was the founding Chief Scientific Officer and Executive Vice President of R&D at ex Capstan Therapeutics, a company developing next generation RNA-based precision medicines. Previously, he held leadership roles at Kite Pharma and Kite, a Gilead Company, including Chief Scientific Officer, Global Head of Translational Medicine and Head of Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Dr. Bot also served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M.D. in Romania in 1993, his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California. Dr. Bot is an inventor and he authored or co-authored more than 200 peer reviewed manuscripts, abstracts, book chapters and monographs and serves in advisory roles for AbbVie Inc, Cartesian Therapeutics, Stand Up 2 Cancer and other organizations.

Dr. Munster is a physician scientist who received her medical degree from the University of Bern, Switzerland. She completed her Internal Medicine training at Indiana University Medical Center and Heme-Onc Fellowship at Memorial Sloan-Kettering Cancer Center, New York where she then served on faculty as a breast cancer specialist. She subsequently joined the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center in Tampa, Florida, as the Scientific Director of Breast Research and Co-Chair of the Experimental Therapeutics Program prior to moving to the University of California, San Francisco. Dr. Munster is the Mariam Moghadam Safinia Distinguished Professor in Residence, the Program Leader for Molecular Oncology, and the Co-Leader of the BRCA Center for Research and Hereditary Cancer Clinic at the Helen Diller Family Comprehensive Cancer Center.
Dr Munster is also the founder and current chief scientific advisor of Alessa Therapeutics, a UCSF spin-off, developing organ selective localized therapeutic interventions. She serves on several NCI study sections including on the steering committee for PREVENT. Additionally, she is the Co-chair of the Experiential Therapeutics Committee at the Alliance of Clinical Trials in Oncology, she chairs the Exam Committee for the American Board of Internal Medicine (ABIM), and advises AnCan, a large national patient advocacy program as a board member.
Her NCI funded basic research laboratory is focused on epigenetic and inherited factors of tumor development and treatment. Dr. Munster’s clinical mission is to translate novel scientific discovery more rapidly to patient care by integrating multi-modality novel treatment strategies and new detection methods through early phase clinical trials with the goal to allow patients with incurable cancer real time and broad access to scientific advances. Much emphasis in her work is placed on early interception and prevention of cancer. Dr Munster has submitted over 20 INDs over the last 10 years helping multiple industry partners to take a novel compound from discovery to clinical testing.
Dr. Munster has published in numerous peer-reviewed scientific journals and textbooks. She has recently authored “Twisting Fate”, a book on the implications of living with a hereditary cancer mutation.

Dr. Michael Kalos is an internationally recognized expert in T cell therapy and immunotherapy, and brings over 28 years of experience and expertise in cell therapy, immunooncology, and oncology vaccines.
Michael is Founder and Managing Director at Next Pillar Consulting, an LLC focused on providing consulting and advising services in the biopharmaceutical and venture space. In addition, Michael serves as Senior Venture Partner and Head of Cell Therapy for Orange Grove Bio and CEO of the Orange Grove Bio sub-co IpinovyxBio, as Executive Venture Partner and co-founder of the Alloy/82VS start-ups Ypsilon Therapeutics and 7×8 Biosciences, and on Corporate and Scientific Advisory Boards for a number of public and private biopharmaceutical companies. In addition to his board and SAB responsibilities, Michael actively serves as an advisory member for international immunotherapy consortia and societies.

Michael has served in a C-suite capacity at cTRL-Therapeutics and ArsenalBio, as Vice President of Immuno-oncology and Oncology Cell Therapies at Janssen, and as Chief Scientific Officer of Immune-oncology at Eli Lilly.

Prior to joining the biopharmaceutical sector, Michael spent 10 years in academia, where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs and is co-inventor of the IP that led to the development and approval of Kymriah, the first approved CART therapy.
Michael has co-authored over 85 peer-reviewed manuscripts, including multiple highly cited articles in high-impact journals that have helped define the space of CAR- and TCR- based T cell therapy, as well as book chapters in the field of cancer immunotherapy, and has over 26 issued patents in the field of cell therapy, immunotherapy, and vaccines.

​Pamela D. Garzone is an experienced pharmaceutical executive with a significant record of achievement in drug development and leadership. She is currently the Chief Development Officer of Anixa Biosciences , a small public biotechnology company focusing on cancer treatments. Prior to Anixa, Pamela was the inaugural Chief Medical Officer of Calibr-Skaggs, the drug development division of Scripps Research. She was at Pfizer for over 10 years, initially as the head of Clinical Pharmacology and advancing to Vice President, Asset Management of the Early Oncology clinical development group, overseeing the strategy and scientific direction of Phase 1 up to Proof-of-Concept studies. Prior to Pfizer, she worked for small to medium sized companies including Elan, Telik, and Jenner Biotherapies. Before joining industry, Dr. Garzone was Assistant Professor, School of Pharmacy University of Pittsburgh and Associate Director of the Center for Pharmacodynamic and Pharmacokinetic Research.

Pamela is an invited speaker at international meetings as well as an author of peer-reviewed scientific articles. Recognized for her strategic, operational, regulatory and scientific leadership, she serves as advisor to executives, venture capitalists and non-profit research foundations engaged in healthcare. She has extensive experience helping boards and committees achieve aggressive goals and fulfill key objectives. Pamela is a member and co-chair of the selection committee of AIM-HI Women’s Venture Competition of the National Foundation for Cancer Research. She is an active angel investor in women’s health companies and serves as chairwomen of a private company developing technologies that address women’s health issues. Pamela has achieved the prestigious Qualified Risk Director designation.

Steven Almo is the Chair of the Department of Biochemistry at the Albert Einstein College of Medicine, where he is Professor of Biochemistry and co-leader of the Cancer Therapeutics Program for the Montefiore Einstein Comprehensive Cancer Center. Dr. Almo holds the Wollowick Family Foundation Chair in Immunology and is Director of Einstein’s Macromolecular Therapeutics Development Facility, a resource dedicated to the development and optimization of protein-based therapeutics. Dr. Almo is recognized for his broad contributions to structural biology, immune regulatory mechanisms and technology development. After obtaining his Bachelor of Science in biology from the Massachusetts Institute of Technology, Dr. Almo earned his Doctor of Philosophy in biophysics from Harvard University. He then completed postdoctoral training in cell biology and biophysics at Johns Hopkins University School of Medicine. His high-resolution structural and functional analyses of the mammalian immune system have resulted in unprecedented understanding of the molecular mechanisms that control immunity and are guiding the development of novel antigen-selective strategies for the treatment of infectious diseases, autoimmune diseases and cancers.

Peter Olagunju brings more than 20 years of experience in clinical development, manufacturing, and technical operations, and has contributed to seven approved products, including PROVENGE®, ZYNTEGLO®, ABECMA®, ADSTILADRIN®, SKYSONA®, and LYFGENIA®. He most recently served as Chief Executive Officer of a Catalio Capital-backed oncology company, which he led from formation through a $14 million seed financing to a successful corporate transaction.

He previously held Chief Operating Officer and Chief Technology Officer roles at TCR² Therapeutics, where he served as the operations lead on the company’s acquisition by Adaptimmune, and has held senior executive positions at FerGene and bluebird bio. Olagunju is Chairman of the Board of March Biosciences and holds an M.B.A. from the University of Washington’s Foster School of Business and a B.S. in Biology from the University of Illinois at Urbana-Champaign.

Kan Xing joined ImmunoScape in 2021 and currently serves as Director for Discovery. Together with his team of scientists, they provide the scientific groundwork to advance and develop ImmuoScape’s platform technology along with other endeavors in immuno-oncology. Before joining ImmunoScape, Kan Xing worked on induced pluripotent stem cell models of vascular diseases as a Research Fellow at Lee Kong Chian School of Medicine in Nanyang Technological University of Singapore. Kan Xing holds a PhD In Virology from the National University of Singapore.